Press Releases

Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants NASHVILLE, Tenn. , April 2, 2024 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, today announced the release of a

2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn. , March 5, 2024 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined

NASHVILLE, Tenn. , Feb. 27, 2024 /PRNewswire/ --   Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024 .

NASHVILLE, Tenn. , Nov. 7, 2023 /PRNewswire/ --   Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $10.1 million during the third quarter of 2023 and $30.2 million

NASHVILLE, Tenn. , Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023 .

NASHVILLE, Tenn. , Oct. 10, 2023 /PRNewswire/ --   Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy 1 detailing the results of the first clinical study investigating the safety and pharmacokinetics of Vibativ ® ( telavancin)

NASHVILLE, Tenn. , Aug. 8, 2023 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2023.

NASHVILLE, Tenn. , Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.   (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023 .

NASHVILLE, Tenn. , June 26, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, today announced the publication of positive results from a clinical study  investigating the safety and pharmacokinetics of Caldolor ® in newborn infants, published

Cumberland initiating Phase II FIGHTING FIBROSIS ™ clinical trial, Newest program in Cumberland's ifetroban pipeline NASHVILLE, Tenn. , May 23, 2023 /PRNewswire/ --  Cumberland Pharmaceuticals Inc.   (Nasdaq:CPIX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the